HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
Yelena Janjigian, MD
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
Loading...
We're glad to see you're enjoying MedEd On The Go… but how about a more personalized experience?
Press cancel to remain on MedEd On The Go. Press the link below or the continue button to keep going.